Novel dendritic cell-based vaccination in late stage melanoma

Schneble, Erika J; Yu, Xianzhong; Wagner, TE; Peoples, George E.

doi:10.4161/hv.29110

Cited by 12 publications

(7 citation statements)

References 65 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, cervical cancer is considered to be highly dependent on human papilloma virus (HPV) and thus it is anticipated, if not already verified, that HPV vaccination will reduce the incidence of cervical cancer (Dochez et al 2014). Melanoma has been treated with a variety of therapies designed to enhance an anti-tumor immune response (Rosenberg 2014;Schneble et al 2014).…”

Section: Introductionmentioning

confidence: 99%

Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA

Butler

Blanck

2015

Cell Tissue Res

View full text Add to dashboard Cite

The Cancer Genome Atlas (TCGA) is primarily oriented towards revealing the status of cancer cells but TCGA RNASeq data have the potential of representing gene expression for a variety of cells that are included during RNA preparation, i.e., cells that cannot be removed from the microenvironment during cancer sample isolation. Thus, we seek to determine whether RNASeq data can be used to pioneer greater precision for immunoscoring. We obtained the RNASeq results for HLA class II genes, the class II transactivator (CIITA) and T-cell receptor (TCR) alpha segments. The data indicated strong degrees of correlation of HLA class II expression with TCR expression. Furthermore, biomarkers of professional antigen-presenting cells also correlated with TCR expression, with the kidney renal papillary cell carcinoma (KIRP) dataset indicative of the highest level, immune function microenvironment. These analyses indicate that an immune function signature, with probable internal HLA class II-TCR verifications, can be obtained from individual TCGA samples; this in turn indicates that such signatures might provide a basis for correlations with prognosis or for convenient indications of therapy options, such as tumor-infiltrating lymphocyte availability for ex-vivo amplification. Although tumor immunoscoring has been proposed, the above analysis represents the first immunoscoring approach that correlates antigen presentation capacity with TCR mRNA expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA

Butler

Blanck

2015

Cell Tissue Res

View full text Add to dashboard Cite

show abstract

“…Their role in the periphery is to take up antigenic proteins that are processed and presented to T lymphocytes at lymphoid organs in combination with major histocompatibility molecules ( 4 , 20 , 21 ). Many clinical trials of immunotherapy have been performed using DC-based vaccines against melanoma since Nestle et al ( 22 ) reported the efficacy of a melanoma lysate or peptide-treated DC vaccine in 1998 ( 23 , 24 ). These studies have confirmed that DC-based vaccines are an efficient, safe and inexpensive method of melanoma treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Early studies revealed many important antigens in human tumor cell lines. They used lysates of human tumor cell lines to pulse DCs for treatment of the same kind of tumor and achieved a certain therapeutic effect ( 4 , 12 , 13 , 24 , 25 ).…”

Section: Discussionmentioning

confidence: 99%

Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines

Gao

Chen³

et al. 2016

Oncology Reports

View full text Add to dashboard Cite

Dendritic cell (DC) vaccines are currently one of the most effective approaches to treat melanoma. The immunogenicity of antigens loaded into DCs determines the treatment effects. Patients treated with autologous antigen-loaded DC vaccines achieve the best therapeutic effects. In China, most melanoma patients cannot access their autologous antigens because of formalin treatment of tumor tissue after surgery. In the present study, we purified heat shock protein 70 (HSP70)-peptide complexes (PCs) from human melanoma cell lines A375, A875, M21, M14, WM-35, and SK-HEL-1. We named the purified product as M-HSP70-PCs, and determined its immunological activities. Autologous HSP70-PCs purified from primary tumor cells of melanoma patients (nine cases) were used as controls. These two kinds of tumor antigenic complexes loaded into DCs were used to stimulate an antitumor response against tumor cells in the corresponding patients. Mature DCs pulsed with M-HSP70-PCs stimulated autologous T cells to secrete the same levels of type I cytokines compared with the autologous HSP70-PCs. Moreover, DCs pulsed with M-HSP70-PCs induced CD8+ T cells with an equal ability to kill melanoma cells from patients compared with autologous HSP70-PCs. Next, we used these PC-pulsed autologous DCs and induced autologous specific CD8+ T cells to treat one patient with melanoma of the nasal skin and lung metastasis. The treatment achieved a good effect after six cycles. These findings provide a new direction for DC-based immunotherapy for melanoma patients who cannot access autologous antigens.

show abstract

“… 40 - 44 Of these studies, implementation of fused DCs and tumor cells hybrids (the so-called dentritoma) seems to be a promising strategy even though some important inadequacies may limit its clinical usefulness as reported for DCs-based vaccination in the late stage melanoma. 45 Combined immunotherapy and antivascular therapy has been proposed as an effective therapeutic modality in mice model bearing B16-F10 melanoma tumors to polarize the TME using a tumor cell-based vaccine (CAMEL peptide as a B16-F10 cell death-inducing agent). The combined therapy was found to induce profound inhibitory impacts as compared to monotherapies, resulting in lessened angiogenesis and increased tumor-infiltrating CD4+, CD8+ and NK cells with lowered suppressor T-lymphocytes (Tregs).…”

Section: Immunization Of Cancermentioning

confidence: 99%

Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies

Barar

Omidi

2017

Bioimpacts

View full text Add to dashboard Cite

A large number of researchers worldwide have conducted various investigations to advance the cell-based immunotherapies and to examine their clinical benefits as an ultimate prevention and/or treatment modalities against life-threatening malignancies. This dominion needs integration of science and technology to change the face of treatment of diseases towards much more personalized medicines. It is now plausible to reprogram the human cells for the prevention and treatment of diseases through various mechanisms such as modulation of immune system, nonetheless we should understand the complexity of biological functions of the cells in a holistic way to be able to manipulate the central dogma of the life to prevent any inadvertent mistake. We should, if not must, comprehend the interrelations of the cellular components (e.g., transport machineries) in the developmental processes of diseases. Still, we do not have a complete image of life, perhaps as expressive barcodes, and many pieces are missing. While completing this puzzle to picture the whole image and examine new treatment modalities, we should take extra caution upon unknown/little-known biological phenomena because trifling modulation/ alteration in the complex systems of the life may result in tremendous impacts. In short, it seems we need to consider malignancies as complex systems and treat them in a holistic manner by targeting its hallmarks. Taken all, the immune system reinforcement would be one of the main foundations in combating detrimental malignancy uprising.

show abstract

Novel dendritic cell-based vaccination in late stage melanoma

Cited by 12 publications

References 65 publications

Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA

Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA

Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines

Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies

Contact Info

Product

Resources

About